GeneMatrix Inc Total Liabilities
GeneMatrix Inc total liabilities. Based on the latest financial reports, GeneMatrix Inc (109820) has total liabilities worth ₩9.72 Billion KRW (≈ $6.59 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check GeneMatrix Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of GeneMatrix Inc (2011–2024)
Total liabilities of GeneMatrix Inc from 2011 to 2024. This chart illustrates how GeneMatrix Inc's total liabilities have evolved over time, based on quarterly financial data. Explore GeneMatrix Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
GeneMatrix Inc Competitors by Total Liabilities
The table below lists competitors of GeneMatrix Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Millcon Steel Public Company Limited
BK:MILL
|
Thailand | ฿15.38 Billion |
|
RENDER CUBE BSAC ZY -10
F:W63
|
Germany | €1.63 Million |
|
Step One Clothing Ltd
AU:STP
|
Australia | AU$8.44 Million |
|
Agung Semesta Sejahtera Tbk PT
JK:TARA
|
Indonesia | Rp42.24 Billion |
|
PIL ITALICA LIFESTYLE LIMITED
NSE:PILITA
|
India | Rs-839.18 Million |
|
Hua Yang Bhd
KLSE:5062
|
Malaysia | RM374.52 Million |
|
Austin Gold Corp
NYSE MKT:AUST
|
USA | $128.82K |
|
Mohenz.Co.Ltd
KQ:006920
|
Korea | ₩19.16 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down GeneMatrix Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of GeneMatrix Inc.
Liquidity & Leverage Metrics
GeneMatrix Inc Total Liabilities Ratios Explained
GeneMatrix Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.26 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GeneMatrix Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GeneMatrix Inc (2011–2024)
The table below shows the annual total liabilities of GeneMatrix Inc from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩9.23 Billion ≈ $6.26 Million |
+12.49% |
| 2023-12-31 | ₩8.21 Billion ≈ $5.56 Million |
+6.34% |
| 2022-12-31 | ₩7.72 Billion ≈ $5.23 Million |
+7.01% |
| 2021-12-31 | ₩7.21 Billion ≈ $4.89 Million |
+51.02% |
| 2020-12-31 | ₩4.78 Billion ≈ $3.24 Million |
-63.84% |
| 2019-12-31 | ₩13.21 Billion ≈ $8.95 Million |
-36.15% |
| 2018-12-31 | ₩20.68 Billion ≈ $14.02 Million |
+209.45% |
| 2017-12-31 | ₩6.68 Billion ≈ $4.53 Million |
-2.43% |
| 2016-12-31 | ₩6.85 Billion ≈ $4.64 Million |
-36.24% |
| 2015-12-31 | ₩10.74 Billion ≈ $7.28 Million |
+108.13% |
| 2014-12-31 | ₩5.16 Billion ≈ $3.50 Million |
-25.15% |
| 2013-12-31 | ₩6.90 Billion ≈ $4.67 Million |
+7.29% |
| 2012-12-31 | ₩6.43 Billion ≈ $4.36 Million |
-6.58% |
| 2011-12-31 | ₩6.88 Billion ≈ $4.66 Million |
-- |
About GeneMatrix Inc
GeneMatrix Inc. develops diagnostic products for various diseases in the field of molecular diagnostics. The company offers products for hepatitis B, hepatitis C, cervical cancer, sexually transmitted infections, respiratory infections, and gastrointestinal infections; vaccines for preventing various diseases; and new natural pharmaceutical materials for health enhancement and treatment. It also … Read more